Phaseline

Companies › GrandPharma (China)

GrandPharma (China): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rivoceranib
Vascular endothelial growth factor receptor 2 inhibitor
KDRPhase 2HCCDec 2027
Yttrium [90Y] Microsphere Injection
Yttrium-90 radioembolization via hepatic artery
–Phase 2HCCDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07334483Yttrium [90Y] Microsphere InjectionPhase 2HCCOncologyDec 2027
NCT07334483RivoceranibPhase 2HCCOncologyDec 2027

Targets

KDR (1)

Companies with the same targets

Hutchmed Exelixis Merck & Co. (MSD) Jiangsu HengRui Medicine Chia Tai Tianqing Pharmaceutical Group Takeda AO GENERIUM Chipscreen Biosciences Avalyn Pharma Mannkind

Companies built like this

Guangzhou Virotech Pharmaceutical Criterium Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.